Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fenaux

Showing results (91-100 of 432) with videos related to

Pageof 44
Sort By:
Cell Cycle (Georgetown, Tex.)|October 26, 2012
Erlotinib antagonizes ABC transporters in acute myeloid leukemiaElodie Lainey, Marie Sébert, Sylvain Thépot, et al.
Blood|July 25, 2008
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia veraJean-Jacques Kiladjian, Bruno Cassinat, Sylvie Chevret, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 13, 2018
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 StudyValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
Haematologica|February 13, 2008
Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromesJean-Jacques Kiladjian, Géraldine Visentin, Emilie Viey, et al.
Haematologica|September 22, 2011
Neurological disorders in essential thrombocythemiaSegolene Billot, Eirini G Kouroupi, Johan Le Guilloux, et al.
Blood Reviews|June 5, 2021
Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learnedEsther N Oliva, Uwe Platzbecker, Pierre Fenaux, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|May 29, 2004
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromesThomas Prébet, Sophie Ducastelle, Stephan Debotton, et al.
Apoptosis : an International Journal on Programmed Cell Death|August 2, 2008
Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemiaJennifer Grosjean-Raillard, Lionel Adès, Simone Boehrer, et al.
Annals of Hematology|February 13, 2008
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromesAristoteles Giagounidis, Pierre Fenaux, Ghulam J Mufti, et al.
Blood|February 1, 2007
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndromePierre Fenaux, Azra Raza, Ghulam J Mufti, et al.
Pageof 44

Showing results (91-100 of 432) with videos related to

Sort By:
Pageof 44
Cell Cycle (Georgetown, Tex.)|October 26, 2012
Erlotinib antagonizes ABC transporters in acute myeloid leukemiaElodie Lainey, Marie Sébert, Sylvain Thépot, et al.
Blood|July 25, 2008
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia veraJean-Jacques Kiladjian, Bruno Cassinat, Sylvie Chevret, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 13, 2018
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 StudyValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
Haematologica|February 13, 2008
Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromesJean-Jacques Kiladjian, Géraldine Visentin, Emilie Viey, et al.
Haematologica|September 22, 2011
Neurological disorders in essential thrombocythemiaSegolene Billot, Eirini G Kouroupi, Johan Le Guilloux, et al.
Blood Reviews|June 5, 2021
Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learnedEsther N Oliva, Uwe Platzbecker, Pierre Fenaux, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|May 29, 2004
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromesThomas Prébet, Sophie Ducastelle, Stephan Debotton, et al.
Apoptosis : an International Journal on Programmed Cell Death|August 2, 2008
Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemiaJennifer Grosjean-Raillard, Lionel Adès, Simone Boehrer, et al.
Annals of Hematology|February 13, 2008
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromesAristoteles Giagounidis, Pierre Fenaux, Ghulam J Mufti, et al.
Blood|February 1, 2007
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndromePierre Fenaux, Azra Raza, Ghulam J Mufti, et al.
Pageof 44